Cannabidiol News Online
SEE OTHER BRANDS

Global take on CBD news

FLUENT Reports First Quarter 2025 Results

- Q1 Revenue Grew 5.91% YoY to $26.7 million
- Ended quarter with $30.7 million of cash and cash equivalents
- New York operations continuing to progress as Buffalo cultivation facility nears completion

TAMPA, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) ("FLUENT" or the "Company"), a vertically-integrated, multi-state cannabis company, today announced its financial and operating results for the first quarter ended March 31, 2025. Unless otherwise indicated, all financial results are presented in U.S. dollars.

Management Commentary

“In Q1 2025, we generated $26.7 million in revenue, a 5.9% increase year-over-year, despite continued price compression and increased market saturation in Florida,” said Robert Beasley, Chief Executive Officer of FLUENT. “While adjusted EBITDA declined to $3.5 million, largely due to softness in Florida, our core fundamentals remain strong. We continue to invest in infrastructure and brand development to support long-term growth. Despite industry-wide challenges this quarter, we remained focused on disciplined execution.”

Beasley added, “In New York, integration of the RIV Capital assets is progressing well, with the Buffalo cultivation facility nearing completion and the FLUENT retail rebrand underway. In Florida, we launched new products and completed construction of the Roza facility, expanding production capacity ahead of our next planned harvest. Our cash position of $30.7 million, up from $8.5 million a year ago, gives us the flexibility to support near-term priorities and long-term growth.”

He concluded, “While macro and regulatory uncertainties remain, we are focused on strengthening our core markets, managing costs, and positioning the company to adapt and grow as market conditions evolve.”

Q1 2025 Financial Highlights (vs. Q1 2024)

Recent Operational Highlights

Company Footprint:

Florida:

New York:

Texas:

Pennsylvania:

The company is actively monitoring legislative developments and is encouraged by the accelerating momentum toward adult-use legalization in Pennsylvania and the potential expansion of the medical program in Texas, both of which represent promising future growth catalysts.

_____________________________
1 Gross profit before fair value adjustments is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates gross profit before fair value adjustments from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.

Conference Call

The Company will host a conference call and live audio webcast today at 4:30 p.m. Eastern time to discuss its financial and operational results, followed by a question-and-answer period.

Date: Thursday, May 29, 2025
Time: 4:30 p.m. Eastern time
Toll-free dial-in number: 1-844-763-8274 (toll -free)
International dial-in number: 1-412-717-9224 (international)

Join Instructions: Participants to ask to be joined into the FLUENT Corp. call.

Link: FLUENT Corp Conference Call

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

The conference call will also be available for replay for up to two weeks via the News & Events section of the Company’s investor relations website at https://investors.getFLUENT.com/.

Forward-Looking Information
Certain information in this news release may constitute forward-looking information within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Company's expectations, estimates, and projections regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available on its SEDAR+ profile at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information visit: https://getfluent.com/ and https://investors.getFLUENT.com/

Investor Relations Contact
investors@getFLUENT.com 

Media Contact:
press@getfluent.com 

Officer Contact:
Robert Beasley, CEO
(850) 972-8077

 
Fluent Corp.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
As of March 31, 2025 and December 31, 2024
(USD '000)
  March 31,
2025
  December 31,
2024
       
Assets      
Current assets      
Cash and cash equivalents $ 30,744     $ 40,106  
Accounts receivable   235       422  
Biological assets   3,298       3,162  
Inventory, net   20,051       15,155  
Prepaid expenses and other current assets   1,824       2,587  
Total current assets $ 56,152     $ 61,432  
       
Property and equipment, net   53,757       52,200  
Intangible assets, net   37,315       37,590  
Right-of-use assets, net   45,523       46,731  
Goodwill   1,525       1,525  
Deferred tax assets   1,248       1,039  
Other assets   6,534       6,476  
Total assets $ 202,053     $ 206,992  
       
Liabilities and shareholders' equity      
Current liabilities      
Accounts payable $ 4,439     $ 6,331  
Accrued expenses   8,923       8,423  
Income taxes payable   1,003       1,003  
Derivative liabilities   1,691       2,148  
Short term provision liability   5,000       4,957  
Current portion of notes payable   458       755  
Lease obligations - current portion   4,943       4,751  
Total current liabilities $ 26,457     $ 28,368  
       
Long-term liabilities      
Notes payable, net of current portion and financing costs   69,261       68,775  
Lease obligations, net of current portion   51,168       51,727  
Deferred tax liability   5,542       4,817  
Uncertain tax position   48,176       43,314  
Long term provision liability   8,980       9,044  
Convertible notes, net   6,729       6,482  
Other long-term liabilities   3,447       3,447  
Total long-term liabilities $ 193,303     $ 187,606  
Total liabilities $ 219,760     $ 215,974  
       
Shareholders' equity      
Share capital   206,419       206,419  
Share-based compensation reserve   7,300       7,275  
Equity conversion feature   7,097       7,097  
Warrants   29,634       29,634  
Accumulated deficit   (266,961 )     (258,211 )
Accumulated other comprehensive income (loss)   (1,196 )     (1,196 )
Total shareholders' equity   (17,707 )     (8,982 )
       
Total liabilities and shareholders' equity $ 202,053     $ 206,992  
       


 
Fluent Corp.
CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)
For the three months ended March 31, 2025 and March 31, 2024
(USD '000) For the three months ended
  March 31,
2025
  March 31,
2024
       
Revenue, net $ 26,717     $ 25,227  
Cost of goods sold   14,195       12,966  
Gross profit before fair value adjustments   12,522       12,261  
       
Fair value adjustments on inventory sold   (301 )     1,628  
Unrealized gain (loss) on changes in fair value of biological assets   3,025       1,047  
Gross profit   15,246       14,936  
       
Operating expenses:      
General and administrative   4,894       3,963  
Sales and marketing   6,319       5,434  
Depreciation and amortization   2,025       1,730  
Share-based compensation   25       49  
Total operating expenses   13,263       11,176  
       
Income from operations   1,982       3,760  
       
Other expense (income):      
Finance costs, net   4,423       4,711  
Gain on change in fair value of derivative liability   (457 )     (1,687 )
Loss on disposal of assets   -       212  
Other expense, net   12       2  
Total other expense   3,978       3,238  
       
Net income (loss) before income taxes   (1,996 )     522  
       
Income tax expense   6,754       4,685  
       
Comprehensive income (loss) $ (8,750 )   $ (4,163 )
       
Net loss per share - basic and diluted $ (0.02 )   $ (0.01 )
               


 
Fluent Corp.
CONSOLIDATED STATEMENTS OF CASH FLOW
For the three months ended March 31, 2025 and March 31, 2024
(USD '000)
  For the three months ended
  March 31,
2025
  March 31,
2024
       
Cash flows used in operating activities      
Net loss $ (8,750 )   $ (4,163 )
       
Adjustments for non-cash items:      
Bargain purchase gain on business combination      
Loss on issuance and extinguishment of debt instruments, net      
Intangible assets impairment      
Unrealized (gain) loss on changes in fair value of biological assets   (3,025 )     (1,047 )
Realized (gain) loss on fair value amounts included in inventory sold   301       (1,628 )
Share-based compensation expense   25       49  
Depreciation and amortization   4,553       3,703  
Accretion and interest expense   4,332       4,686  
Net change in fair value of derivative   (457 )     (1,687 )
Loss on dispositions of fixed assets   -       212  
Uncertain tax position   4,862       -  
Deferred tax expense   516       1,216  
Changes in non-cash working capital      
Accounts receivable   187       (17 )
Inventory   3,279       3,939  
Biological assets   (5,587 )     (3,551 )
Prepaid expenses and other current assets   763       747  
Right of use assets / liabilities   (1,000 )     (1,317 )
Other assets   (58 )     (90 )
Accounts payable   (1,892 )     630  
Accrued expenses   500       (4,192 )
Income taxes   -       6,938  
Other long-term liabilities   -       (375 )
Net cash provided by operating activities $ (1,451 )   $ 4,053  
       
Cash flows used in investing activities      
Purchase of property and equipment $ (4,179 )   $ (2,948 )
Net cash provided by used in investing activities $ (4,179 )   $ (2,948 )
       
Cash flows provided by used in financing activities      
Principal repayments of notes payable   (2,681 )     (2,340 )
Payment of lease obligations   (1,051 )     (765 )
Net cash used in financing activities $ (3,732 )   $ (3,105 )
       
Net decrease in cash and cash equivalents $ (9,362 )   $ (2,000 )
       
Cash, beginning of period   40,106       10,521  
       
Cash, end of period $ 30,744     $ 8,521  
       


 
Fluent Corp.
EBITDA AND ADJUSTED EBITDA CALCULATION
For the three months ended March 31, 2025 and March 31, 2024
(USD '000)
     
  For the three months ended
  March 31,
2025

  March 31,
2024
Net loss $ (8,750 )   $ (4,163 )
Finance costs, net   4,423       4,711  
Income taxes   6,754       4,685  
Depreciation and amortization   4,014       3,702  
EBITDA $ 6,441     $ 8,935  
     
     
  For the three months ended
  March 31,
2025

  March 31,
2024
EBITDA $ 6,441     $ 8,935  
Change in fair value of biological assets   (2,724 )     (2,675 )
Change in fair market value of derivative   (457 )     (1,687 )
Professional fees(1)   74       1,789  
One-time employee costs(2)   133       160  
Share-based compensation   25       49  
Loss on disposal of assets   -       212  
Other non-recurring expense   12       2  
Adjusted EBITDA $ 3,504     $ 6,785  
     
(1) Legal and professional fees associated with potential transactions and professional fees associated with prior periods.
(2) Severance and relocation costs.
     

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service